
BioNTech SE
BNTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 14, 2026 | Canaccord Genuity | $132.00(+48%) | $89.01 | TheFly | |
| Oct 7, 2026 | Morgan Stanley | Terence Flynn | $114.00(+19%) | $95.63 | TheFly |
| Sep 16, 2026 | Berenberg Bank | $140.00(+45%) | $96.69 | TheFly | |
| Sep 8, 2026 | BMO Capital | Evan David Seigerman | $105.00(+1%) | $103.76 | StreetInsider |
| Aug 31, 2026 | Canaccord Genuity | $136.00(+33%) | $102.08 | TheFly | |
| Aug 5, 2026 | Canaccord Genuity | $142.00(+55%) | $91.35 | TheFly | |
| Jul 8, 2026 | Morgan Stanley | $119.00(+26%) | $94.29 | TheFly | |
| May 27, 2026 | UBS | $135.00(+46%) | $92.25 | TheFly | |
| May 21, 2026 | Bernstein | $96.00(+6%) | $90.93 | TheFly | |
| May 6, 2026 | Canaccord Genuity | $158.00(+65%) | $95.50 | TheFly | |
| Apr 10, 2026 | Morgan Stanley | Terence Flynn | $126.00(+35%) | $93.38 | TheFly |
| Mar 11, 2026 | BMO Capital | Evan David Seigerman | $128.00(+41%) | $90.52 | StreetInsider |
| Mar 10, 2026 | Jefferies | Akash Tewari | $138.00(+65%) | $83.89 | StreetInsider |
| Mar 10, 2026 | Truist Financial | Asthika Goonewardene | $155.00(+85%) | $83.89 | StreetInsider |
| Mar 10, 2026 | Morgan Stanley | $128.00(+53%) | $83.89 | StreetInsider | |
| Feb 2, 2026 | Leerink Partners | $113.00(-1%) | $113.75 | TheFly | |
| Jan 16, 2026 | Goldman Sachs | $142.00(+34%) | $106.07 | TheFly | |
| Dec 11, 2025 | Berenberg Bank | Harry Gillis | $155.00(+62%) | $95.68 | TheFly |
| Dec 11, 2025 | H.C. Wainwright | Raghuram Selvaraju | $140.00(+44%) | $96.91 | StreetInsider |
| Nov 3, 2025 | Morgan Stanley | $134.00(+29%) | $103.95 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| UBS | maintain | Buy | Nov 4, 2026 |
| Evercore ISI Group | maintain | Outperform | Nov 4, 2026 |
| Wells Fargo | maintain | Overweight | Nov 4, 2026 |
| Morgan Stanley | maintain | Overweight | Nov 4, 2026 |
| Canaccord Genuity | maintain | Buy | Oct 14, 2026 |
| Morgan Stanley | maintain | Overweight | Oct 7, 2026 |
| BMO Capital | downgrade | Outperform →Market Perform | Sep 8, 2026 |
| Canaccord Genuity | maintain | Buy | Aug 31, 2026 |
| Citigroup | maintain | Buy | Aug 5, 2026 |
| Evercore ISI Group | maintain | Outperform | Aug 5, 2026 |
| Morgan Stanley | maintain | Overweight | Jul 8, 2026 |
| UBS | upgrade | Neutral →Buy | May 27, 2026 |
| Canaccord Genuity | maintain | Buy | May 6, 2026 |
| Wells Fargo | maintain | Overweight | May 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 27, 2026 |
| Morgan Stanley | maintain | Overweight | Apr 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2026 |
| Citigroup | maintain | Buy | Mar 11, 2026 |
| Morgan Stanley | maintain | Overweight | Mar 11, 2026 |
| BMO Capital | maintain | Outperform | Mar 11, 2026 |
| TD Cowen | maintain | Hold | Mar 11, 2026 |
| Canaccord Genuity | maintain | Buy | Mar 11, 2026 |
| Jefferies | maintain | Buy | Mar 10, 2026 |
| Goldman Sachs | upgrade | Neutral →Buy | Jan 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 10, 2025 |
Earnings History
Next report: Mar 9, 2027 · EPS est. $-1.90| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $0.83 | $0.76 | $1.46B | $1.17B |
| Aug 4, 2026 | $-3.70 | $-2.40 | $120.6M | $180.2M |
| May 5, 2026 | $-2.43 | $-2.54 | $136.4M | $207.4M |
| Mar 10, 2026 | $-1.44 | $-0.22 | $1.07B | $902.3M |
| Nov 3, 2025 | $-0.14 | $-1.12 | $1.78B | $843.7M |
| Aug 4, 2025 | $-1.82 | $-2.69 | $307.1M | $177.8M |
| May 5, 2025 | $-1.82 | $-2.48 | $200.4M | $215.1M |
| Mar 10, 2025 | $1.15 | $0.46 | $1.23B | $1.18B |
News
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.
BioNTech is rated Hold due to a narrowing pipeline, negative cash flow, and reliance on two main assets: pumitamig and gotistobart. Q3 profit is less meaningful than the widening gap between reported earnings and cash economics, with liquid assets declining despite reported net income. BNTX's revised revenue outlook reflects only a modest improvement, and ongoing cash burn, portfolio retrenchment, and pipeline concentration heighten risk.
BioNTech SE ( BNTX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Douglas Maffei - Vice President of Strategy & Investor Relations Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Divisi…
BioNTech NASDAQ: BNTX reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology pipeline, including lung cancer, breast cancer and mRNA cancer immunotherapy programs.
Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead's TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median ov…
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial.
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) with trastuzumab pamirtecan (BNT323/DB-1303) compared to investigator's choice of chemotherapy in chemotherapy-naïve patie…
MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy…
A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked favorable on their face. Moderna stock is at $184.
BioNTech, Gilead to test drug combination in advanced breast cancer trial
MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate (“ADC”) sacituzumab govitecan (Trodelvy®) as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (“TNBC”). Pumitamig is an investigational bispecific immunomodulator …
MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
MAINZ, Germany, October 19, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its late-stage oncology pipeline with 16 abstracts spanning the Company's tumor focus areas, including lung and breast cancer, at the European Society for Medical Oncology (“ESMO”) 2026 Congress held in Madrid, Spain, from October 23–27, 2026.
BioNTech needs new products to kickstart sales and earnings growth. But two of the company's candidates have experienced setbacks recently.
A 16.6 billion euro cash balance gives BioNTech room to fund trials, partnerships, and a $1 billion share repurchase program. With 14 pivotal trials underway, including seven for pumitamig, BioNTech's oncology pipeline is moving well beyond early-stage research.
BioNTech (NASDAQ: BNTX - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Profitability This table compares BioNTech and MiMedx Group's net
Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to $214.